<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780217</url>
  </required_header>
  <id_info>
    <org_study_id>MVR-T3011-003</org_study_id>
    <nct_id>NCT04780217</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Intravenous T3011 Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 When Administered Via Intravenous Infusion as a Single Agent and in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmVira Pharma Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmVira Pharma Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2a open label study to evaluate the safety and preliminary efficacy of&#xD;
      intravenous T3011 given alone and in combination with intravenous pembrolizumab in&#xD;
      participants with advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2a, open-label, first-in-human study of T3011 given via intravenous (IV)&#xD;
      infusion as a single agent and in combination with IV pembrolizumab in participants with&#xD;
      advanced or metastatic solid tumors. The Phase 1 Part A portion of the study is a single&#xD;
      agent dose escalation which will use a 3+3 design to evaluate escalating doses of T3011.&#xD;
      Total enrollment will depend on the toxicities and/or activity observed, with approximately&#xD;
      24 evaluable participants enrolled. Once the IV T3011 RP is established, the Phase 1 Part B&#xD;
      part of the study will begin. Phase 1 Part B is IV T3011 in combination with IV pembrolizumab&#xD;
      dose escalation which will use a 3+3 design to evaluate escalating doses of IV T3011 in&#xD;
      combination with IV pembrolizumab. Total enrollment will depend on the toxicities and/or&#xD;
      activity observed, with approximately 18 evaluable participants enrolled. Upon completion of&#xD;
      Phase 1 Part B, Phase 2a will begin. The safety, tolerability, and preliminary efficacy of IV&#xD;
      T3011 given in combination with IV pembrolizumab will be evaluated in 15 participants with&#xD;
      histologically or pathologically confirmed metastatic NSCLC (Arm A) and 15 participants with&#xD;
      advanced solid tumors with metastasis in either the liver and/or lung (Arm B).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of escalating doses of single agent IV T3011 (Part A) and of IV T3011 in combination with pembrolizumab (Part B).</measure>
    <time_frame>Up to 2 years from first dose of T3011</time_frame>
    <description>Incidence and characteristics of TEAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize DLTs and identify the MTD and/or the RD of single agent IV T3011 (Part A) and the MTD and/or the RP2D of IV T3011 in combination with pembrolizumab (Part B).</measure>
    <time_frame>From first dose of T3011 through Cycle 1 (approximately 21 days)</time_frame>
    <description>Incidence of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the safety and tolerability of the RP2D of IV T3011 in combination with pembrolizumab selected from Phase 1 Part B in disease specific cohorts.</measure>
    <time_frame>Up to 2 years from first dose of T3011</time_frame>
    <description>Incidence and characteristics of TEAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 2 years from first dose of T3011</time_frame>
    <description>ORR is defined as the proportion of participants who have a partial response (PR) or complete response (CR) to intervention, based on investigator assessments by RECIST v1.1 and iRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 2 years from first dose of T3011</time_frame>
    <description>DCR is defined as the percentage of participants who have achieved CR, PR, or stable disease (SD) based on investigator assessments per RECIST v1.1 and iRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 2 years from first dose of T3011</time_frame>
    <description>DOR is defined as the time from the first met CR or PR until disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable response (DR)</measure>
    <time_frame>Up to 2 years from first dose of T3011</time_frame>
    <description>DR is defined as objective response (CR or PR) according to RECIST v1.1 and iRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years from first dose of T3011</time_frame>
    <description>PFS is defined as the time from enrollment to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first per RECIST v1.1 and iRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 1 year from last dose of T3011</time_frame>
    <description>OS is defined as the time from enrollment to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative viral DNA level of T3011 in urine and saliva.</measure>
    <time_frame>Up to 2 years from first dose of T3011</time_frame>
    <description>To evaluate viral shedding in participants dosed with IV T3011.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative measurements of blood viral DNA level, serum IL-12 and anti-PD-1 antibody concentration.</measure>
    <time_frame>Up to 2 years from first dose of T3011</time_frame>
    <description>To evaluate the pharmacokinetic (PK) in participants dosed with IV T3011.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-herpes simplex virus type 1 (HSV-1) immunoglobulin G (IgG) and anti-PD-1 idiotypic antibody.</measure>
    <time_frame>Up to 2 years from first dose of T3011</time_frame>
    <description>To evaluate the immunogenicity in participants dosed with IV T3011.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Metastasis in Lung</condition>
  <condition>Metastasis in Liver</condition>
  <condition>Solid Tumor</condition>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Phase 1 Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T3011 Single Agent Dose Escalation in participants with solid tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation of Combination T3011 + pembrolizumab in participants with solid tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP2D T3011 + pembrolizumab in participants with NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP2D T3011 + pembrolizumab in participants with advanced solid tumors with metastasis in either liver and/or lung</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T3011</intervention_name>
    <description>T3011 will be administered in a 10 mL solution as an IV infusion</description>
    <arm_group_label>Phase 1 Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>T3011 + pembrolizumab</intervention_name>
    <description>T3011 will be administered in a 10 mL solution as an IV infusion followed by administration of IV pembrolizumab</description>
    <arm_group_label>Phase 1 Part B</arm_group_label>
    <arm_group_label>Phase 2a Arm A</arm_group_label>
    <arm_group_label>Phase 2a Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants with one of the following cancers:&#xD;
&#xD;
               -  Pathologically confirmed, locally recurrent or metastatic solid tumors&#xD;
&#xD;
               -  Histologically or cytologically confirmed NSCLC that is recurrent or metastatic&#xD;
&#xD;
               -  Histologically or cytologically diagnosed advanced solid tumors with metastasis&#xD;
                  in liver and/or lung&#xD;
&#xD;
          2. Disease progression after SOC therapy or in the opinion of the Investigator unlikely&#xD;
             to benefit from SOC therapy.&#xD;
&#xD;
          3. Age 18 years or older.&#xD;
&#xD;
          4. Measurable disease per RECIST version 1.1.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.&#xD;
&#xD;
          6. Life expectancy &gt; 12 weeks.&#xD;
&#xD;
          7. Demonstrate adequate organ function as defined by acceptable laboratory testing&#xD;
             results.&#xD;
&#xD;
          8. Women of child-bearing potential (WCBP) and men must agree to use adequate&#xD;
             contraception prior to study entry, while on study treatment, and for six months after&#xD;
             receiving last dose of T3011. WCBP must have a negative serum pregnancy test prior to&#xD;
             C1D1.&#xD;
&#xD;
          9. Last dose of previous anticancer therapy â‰¥ 21 days, radiotherapy &gt; 21 days, or&#xD;
             surgical intervention &gt; 21 days prior to the first dose of T3011.&#xD;
&#xD;
         10. Recovered from all prior anticancer therapy toxicities.&#xD;
&#xD;
         11. Willingness to provide fresh tumor biopsy specimens as specified in the Schedule of&#xD;
             Assessments.&#xD;
&#xD;
         12. Capable of understanding and complying with protocol requirements.&#xD;
&#xD;
         13. Signed and dated institutional review board/independent ethics committee (IRB/IEC)&#xD;
             approved informed consent form (ICF) before any protocol-directed screening procedures&#xD;
             are performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with another oncolytic virus or cellular therapy.&#xD;
&#xD;
          2. Previous unacceptable intolerance to anti-PD-1 monoclonal antibody.&#xD;
&#xD;
          3. Requires continued concurrent systemic therapy with any drug active against HSV.&#xD;
&#xD;
          4. Live vaccines within 4 weeks of initiation of study treatment.&#xD;
&#xD;
          5. Primary or acquired immunodeficient states.&#xD;
&#xD;
          6. Pregnant or lactating.&#xD;
&#xD;
          7. Splenectomy, previous allogenic tissue/solid organ transplant.&#xD;
&#xD;
          8. Active hepatitis B virus, hepatitis C virus, or a positive serological test at&#xD;
             Screening.&#xD;
&#xD;
          9. Active autoimmune disease or medical conditions requiring chronic steroid.&#xD;
&#xD;
         10. Untreated and/or symptomatic metastatic central nervous system (CNS) disease.&#xD;
&#xD;
         11. History of seizure disorders within 6 months of Screening.&#xD;
&#xD;
         12. Active oral or skin herpes lesion at Screening.&#xD;
&#xD;
         13. Congestive heart failure, active coronary artery disease, unevaluated new onset angina&#xD;
             within 3 months or unstable angina, or clinically significant cardiac arrhythmias.&#xD;
&#xD;
         14. History of allergic reactions attributed to compounds of similar biological&#xD;
             composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or their excipients.&#xD;
&#xD;
         15. Known or suspected active infection with SARS-CoV-2 virus.&#xD;
&#xD;
         16. Other systemic conditions or organ abnormalities that, in the opinion of the&#xD;
             Investigator, may interfere with the conduct and/or interpretation of the current&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ImmVira Pharma Co. LTD</last_name>
    <phone>781-718-5121</phone>
    <email>MVRT3011003@immviragroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiaxin Niu, MD, PhD</last_name>
      <email>MVRT3011003@immviragroup.com</email>
    </contact>
    <investigator>
      <last_name>Jiaxin Niu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health - Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William J Edenfield, MD</last_name>
      <email>MVRT3011003@immviragroup.com</email>
    </contact>
    <investigator>
      <last_name>William J Edenfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith McKean, MD</last_name>
      <email>MVRT3011003@immviragroup.com</email>
    </contact>
    <investigator>
      <last_name>Meredith McKean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minal Barve, MD</last_name>
      <email>MVRT3011003@immviragroup.com</email>
    </contact>
    <investigator>
      <last_name>Minal Barve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.immvira-theravir.com/</url>
    <description>ImmVira Pharma Co. LTD</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 6, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

